Liquidia says its October settlement with United Therapeutics gives certainty, and its October 2026 referral rate was 75% of its Q3 daily rate. It plans over 50% operating margins in 2027 and 10 clinical trials next year, three registrational.
LQDA · Liquidia Corp
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Liquidia reported Eutrepia third-quarter net product sales of $222.7 million, up $52 million, or 31% from last quarter. A $389.7 million settlement charge drove a $236.3 million net loss, while cash ended at $396.1 million before settlement payments.
Liquidia Corporation reported a $236.3 million net loss for the third quarter of 2026, including a $389.7 million litigation settlement charge. Its October 13, 2026 global settlement with United Therapeutics resolved pending lawsuits and kept YUTREPIA available without disruption.
Liquidia settled all outstanding litigation with United Therapeutics Corporation (UTC) on October 13, 2026, agreeing to pay $330.4 million and remove PH-ILD from YUTREPIA’s label. Nine-month product sales rose to $523.0 million, while cash and equivalents reached $396.1 million.
Liquidia Technologies, Inc. settled all ongoing litigation with United Therapeutics Corporation, will remove YUTREPIA’s PH-ILD indication, and will pay $175.0 million net plus $145.4 million; preliminary third quarter 2026 YUTREPIA net product sales were $222.7 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 10, 2026TL;DR. YUTREPIA net product sales increased 31% to $222.7 million, adjusted EBITDA reached $140.5 million for a fifth consecutive quarterly increase, cash reached $396.1 million before settlement payments, and October shipments reached their highest level since launch. Risks include the $389.7 million settlement charge and $380.7 million cash obligation, PH-ILD label removal and promotion cessation, referral volatility, higher R&D and SG&A expenses, and the settlement's limited protection for future indications and products.
- + Third-quarter net product sales increased 31% to $222.7 million, including $212.2 million of paid patient demand. new
- + Cash and cash equivalents increased to $396.1 million before settlement payments. new
- + The prescriber base reached approximately 1,300, with greater depth of prescribing and expanding PAH adoption. new
- − Third-quarter GAAP net loss was $236.3 million, reflecting a $389.7 million litigation settlement charge. new
- − The settlement does not protect indications beyond PAH or new treprostinil products, and United Therapeutics may assert patents against development programs. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Mentioned in fund letters
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $140.5M | third quarter of 2026 | — |
|
|
|||
| Paid patient demand | $212.2M | third quarter of 2026 | — |
| Prescriber base | 1,300 | through October 2026 | — |
| prescribers | 1,300 | Q3 2026 | — |
| Prescribers who have written a PAH script since launch | 77% | since launch | — |
| Prescribers who have written for two or more patients | 60% | as of October 31, 2026 | — |
| Referrals including a PAH diagnosis | 70% | September 2026 | — |
| YUTREPIA prescribers | 1,300 | Launch to Date (LTD) through Oct'26 | — |
| YUTREPIA® (treprostinil) inhalation powder net product sales | $222.74M | FY2026 Q3 | +331.1% |
|
|
|||
| Annualized net product sales run-rate | $682M | exited Q2 2026 | — |
| Patients started on treatment since launch in June 2025 | 5,000 | between launch in June 2025 and July 31, 2026 | — |
| Prescribers who referred patients for YUTREPIA | 1,100 | through 31-Jul 2026 | — |
| Prescribers with 5+ referrals | 30% | through 31-Jul 2026 | — |
| Prescription to patient start conversion rate | 85% | as of July 31, 2026 | — |
| Total number of prescribers since launch | 1,100 | as of July 31, 2026 | — |
| Unique patient prescriptions (YUTREPIA) | 5,900 | through 31-Jul 2026 | — |
| Unique patient prescriptions since launch in June 2025 | 5,900 | between launch in June 2025 and July 31, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LQDA
this stock
Liquidia Corp
|
$5.11B | +64.5% | +1031.2% | — | 19.4% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$69.14B | +38.8% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$52.00B | +7.6% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$49.73B | +36.6% | +4.3% | 96.9 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 22
Liquidia says its October settlement with United Therapeutics gives certainty, and its October 2026 referral rate was 75% of its Q3 daily rate. It plans over 50% operating margins in 2027 and 10 clinical trials next year, three registrational.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LQDA | +10.4% | +56.1% | -8.5% | +25.9% | +64.5% |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | +12.7% | +60.8% | -5.6% | +29.0% | +57.1% |